27/03/2019 20:01:38

Stryker announces new Vice President, Chief Legal Officer

Kalamazoo, Michigan, March 27, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that Rob Fletcher will be joining the company as Vice President, Chief Legal Officer effective April 22, 2019. Mike Hutchinson will be transitioning from his current role to serve as Advisor to the Chief Executive Officer through May 2020.

Mr. Hutchinson has most recently served as Vice President, Chief Legal Officer responsible for the Legal, Compliance and Corporate Secretary functions. “We would like to thank Mike for the many contributions he has made to the company and for his demonstrated commitment to our success and robust growth,” said Kevin Lobo, Chairman and Chief Executive Officer. “Mike has strengthened our global legal and compliance capabilities and guided our company through many complex matters. I wish Mike the best in this new chapter of his career." 

Mr. Fletcher joins Stryker after almost 15 years at Johnson & Johnson during which he held multiple legal leadership roles including General Counsel for both the Medical Devices and Pharmaceutical sectors. Most recently, Mr. Fletcher held the role of Worldwide Vice President, Litigation. Mr. Fletcher brings extensive global experience, demonstrated success in a large, med-tech company and deep leadership experience managing complex business issues and opportunities.

Prior to joining Johnson & Johnson, Mr. Fletcher served as corporate counsel for General Electric Aircraft Engines, which included significant work in mergers, acquisitions, joint ventures and divestitures. Before GE, Mr. Fletcher was in private legal practice at the Ohio law firm Katz Teller in the firm’s corporate and real estate department. He earned his B.A. degree from The Ohio State University and a J.D. from Boston College Law School.

Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.


For investor inquiries please contact:

Katherine A. Owen, Vice President, Strategy & Investor Relations at 269-385-2600 or katherine.owen@stryker.com

For media inquiries please contact:

Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385-2600 or yin.becker@stryker.com

Related content
24 Jun - 
Stryker to host conference call on July 25, 2019
01 May - 
Stryker to participate in Bank of America Merrill Lynch..
01 May - 
Stryker declares a $0.52 per share quarterly dividend

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg


EuroInvestor: In Focus


EuroInvestor: In Focus


EuroInvestor: In Focus

Most read news

  • 24 hours
  • 48 hours
  • 1 week
uBreakiFix Expands Dallas Footprint With Grand Prairie Store
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Translate Bio Appoints George Demetri, M.D., to its Board of Directors
Aemetis India Expands Revenues to $50 Million Per Year Run Rate Driven by Biodiesel Shipments to Large Refiners
American Premium Water Corp (OTC: HIPH) Announces Singleseed.com as Launch Retailer for its Pet CBD Water Product

Related stock quotes

Stryker Corporation 205.49 -0.4% Stock price decreasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
16 July 2019 04:05:09
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190703.1 - EUROWEB1 - 2019-07-16 05:05:09 - 2019-07-16 04:05:09 - 1000 - Website: OKAY